JSPR Jasper Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1788028 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-73.0%
TTM EPS YoY184.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-153.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets14.2%
Debt / equity—
Current ratio10.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-106.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.00M | — | — | — | — | — | — | — |
| Cost of revenue | $4.32M | $3.58M | $3.62M | $6.76M | $9.35M | $15.77M | $9.76M | $13.17M |
| Gross profit | $3.68M | — | — | — | — | — | — | — |
| R&D expense | $8.33M | $5.13M | $5.81M | $11.36M | $14.39M | $21.20M | $16.16M | $19.77M |
| SG&A expense | $6.36M | $4.07M | $5.14M | $4.48M | $4.78M | $5.88M | $5.64M | $5.51M |
| Operating income | -$144.17M | -$9.21M | -$10.95M | -$15.84M | -$19.17M | -$27.08M | -$21.80M | -$25.29M |
| Net income | -$144.46M | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -$21.24M | -$24.32M |
| EBITDA | -$144.16M | $11.79M | -$10.93M | -$15.55M | -$18.97M | -$26.78M | -$21.52M | -$25.04M |
| EPS (basic) | -10.19 | -0.10 | -0.04 | — | -32.08 | -1.74 | -1.41 | — |
| EPS (diluted) | -10.19 | -0.10 | -0.04 | — | -32.08 | -1.74 | -1.41 | — |
| Weighted avg. shares (diluted) | 1.08M | 28.70M | 28.67M | — | 584,056 | 15.33M | 15.02M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $135.35M | $7.31M | $14.14M | $28.69M | $51.32M | $39.93M | $49.22M | $72.05M |
| Receivables | $8.00M | — | — | — | — | — | — | — |
| Current assets | $147.27M | $11.57M | $20.29M | $34.65M | $54.56M | $42.97M | $53.17M | $75.81M |
| PP&E, net | $57,000 | $60,000 | $81,000 | $102,000 | $1.10M | $1.33M | $1.60M | $1.88M |
| Total assets | $147.42M | $11.80M | $21.18M | $35.78M | $57.47M | $46.47M | $57.60M | $79.90M |
| Current liabilities | $13.91M | $7.84M | $9.00M | $13.20M | $21.04M | $20.50M | $12.33M | $15.24M |
| Total liabilities | $20.89M | $10.39M | $17.78M | $31.63M | $45.90M | $22.96M | $15.35M | $18.23M |
| Shareholders' equity | -$140.25M | $1.41M | $3.40M | $4.15M | $11.57M | $23.50M | $42.24M | $61.67M |
| Shares outstanding | 1.11M | 28.08M | 28.00M | 933,242 | 27.98M | 16.22M | 15.02M | 15.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.50M | -$6.92M | -$14.55M | -$21.87M | -$17.00M | -$15.45M | -$22.84M | -$21.13M |
| Capital expenditure | — | — | — | — | $0 | — | — | — |
| Free cash flow | — | — | — | — | -$17.00M | — | — | — |
| Investing cash flow | $7.70M | — | — | $0 | $0 | $1,000 | $4,000 | -$76,000 |
| Financing cash flow | $125.83M | — | — | -$340,000 | $28.39M | — | — | $345,000 |
| Depreciation & amortization | $16,000 | $21.00M | $21,000 | $290,000 | $200,000 | $300,000 | $279,000 | $245,000 |
| Stock-based compensation | $1.22M | $764,000 | $423,000 | $1.66M | $1.42M | $1.82M | $1.81M | $1.97M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.